1-50 of 214
Keywords: cancer
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Biochem Soc Trans (2023) BST20221400.
Published: 04 May 2023
... for this article was enabled by the participation of the University of Geneva in an all-inclusive Read & Publish agreement with Portland Press and the Biochemical Society under a transformative agreement with Individual. cancer cell cycle cryo-electron microscopy enzyme–substrate interactions...
Biochem Soc Trans (2023) 51 (2): 771–781.
Published: 06 April 2023
...Larissa Tinô de Carvalho-Silva; Ana Gabriela C. Normando; Jamile de Oliveira Sá; Erison Santana dos Santos; Tatiane De Rossi; Ariane Fidelis Busso-Lopes; Ana Karina de Oliveira; Adriana F. Paes Leme Cancer is a significant cause of death, precluding increasing life expectancy worldwide...
Biochem Soc Trans (2023) 51 (2): 597–612.
Published: 20 March 2023
... response in HCC and might also have validity for predicting responses to immunotherapy in other cancers. In this review, we explore the immunosuppressive mechanisms and interactions of oncofetal cells in the TME of HCC and their potential implications for immunotherapy response. Correspondence: Ankur...
Biochem Soc Trans (2023) 51 (1): 447–456.
Published: 23 January 2023
... that novel creative ideas continue to be important to exterminate RAS in cancer and other RAS pathway-driven diseases, such as RASopathies. Therefore, high affinity macromolecular binders raised against the effector lobe can potently inhibit RAS signalling. In addition to classical antibodies (∼150 kDa...
Includes: Supplementary data
Biochem Soc Trans (2023) 51 (1): 57–70.
Published: 11 January 2023
... in patients with advanced cancer, dulanermin was shown to have a tolerable safety profile; however, its observed anticancer activity was limited [ 22 ]. Of note, the mean terminal phase half-life ( t 1/2 ) of rhTRAIL ranges from 0.56 to 1.02 h, likely restricting its ability to reach tumor cells [ 22 , 23...
Biochem Soc Trans (2022) 50 (6): 1885–1895.
Published: 13 December 2022
...Aristeidis Panagiotis Sfakianos; Rebecca Mallory Raven; Anne Elizabeth Willis Protein synthesis is dysregulated in the majority of cancers and this process therefore provides a good therapeutic target. Many novel anti-cancer agents are directed to target the initiation stage of translation, however...
Biochem Soc Trans (2022) 50 (5): 1447–1456.
Published: 25 October 2022
...Katherine L.B. Borden Typically, cancer is thought to arise due to DNA mutations, dysregulated transcription and/or aberrant signalling. Recently, it has become clear that dysregulated mRNA processing, mRNA export and translation also contribute to malignancy. RNA processing events result in major...
Biochem Soc Trans (2022) 50 (4): 1119–1128.
Published: 28 July 2022
...Gaoyuan Wang; Sarah T. Diepstraten; Marco J. Herold BFL-1 is an understudied pro-survival BCL-2 protein. The expression of BFL-1 is reported in many cancers, but it is yet to be clarified whether high transcript expression also always correlates with a pro-survival function. However, recent...
Biochem Soc Trans (2022) 50 (3): 1245–1257.
Published: 17 June 2022
...Ryan Lusby; Philip Dunne; Vijay K. Tiwari Activating invasion and metastasis are one of the primary hallmarks of cancer, the latter representing the leading cause of death in cancer patients. Whilst many advances in this area have been made in recent years, the process of cancer dissemination...
Biochem Soc Trans (2022) 50 (2): 975–985.
Published: 06 April 2022
...Dana Beiki; Ian M. Eggleston; Charareh Pourzand 5-Aminolevulinic acid-based photodynamic therapy (ALA-PDT) was first implemented over three decades ago and has since been mainly part of clinical practice for the management of pre-cancerous and cancerous skin lesions. Photodynamic therapy relies...
Biochem Soc Trans (2022) 50 (2): 825–837.
Published: 28 March 2022
...Adithya Balasubramanian; Thomas John; Marie-Liesse Asselin-Labat Evading immune destruction is one of the hallmarks of cancer. A key mechanism of immune evasion deployed by tumour cells is to reduce neoantigen presentation through down-regulation of the antigen presentation machinery. MHC-I and MHC...
Biochem Soc Trans (2022) 50 (1): 473–485.
Published: 07 February 2022
... and discuss new strategies to effectively target this E3 enzyme. Correspondence: Simona Polo ( simona.polo@ifom.eu ) 4 11 2021 18 1 2022 18 1 2022 © 2022 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 2022 cancer E3 ubiquitin-protein...
Biochem Soc Trans (2021) 49 (6): 2727–2736.
Published: 25 November 2021
... integrity. Increasing evidence indicates that chromatin homeostasis plays a key role in the cellular response to TRCs as well as in the preservation of genome integrity. Indeed, chromatin regulating enzymes are frequently mutated in cancer cells, a common characteristic of which is genome instability...
Biochem Soc Trans (2021) 49 (5): 2397–2410.
Published: 28 September 2021
...W. Douglas Fairlie; Erinna F. Lee The deregulation of apoptosis is a key contributor to tumourigenesis as it can lead to the unwanted survival of rogue cells. Drugs known as the BH3-mimetics targeting the pro-survival members of the BCL-2 protein family to induce apoptosis in cancer cells have...
Biochem Soc Trans (2021) 49 (4): 1841–1853.
Published: 02 August 2021
...Ana Sayuri Yamagata; Paula Paccielli Freire Cancer cachexia is associated with deficient response to chemotherapy. On the other hand, the tumors of cachectic patients remarkably express more chemokines and have higher immune infiltration. For immunogenicity, a strong induction of the unfolded...
Biochem Soc Trans (2021) 49 (3): 1425–1442.
Published: 01 July 2021
... GTPases in the context of the membrane. The role of Cdc42 in cancer is well established but the molecular details of its action are still being uncovered. Here we review alterations found to Cdc42 itself and to key components of the signal transduction pathways it controls in cancer. Given the challenges...
Biochem Soc Trans (2021) 49 (3): 1041–1054.
Published: 22 June 2021
... of enhancer function could be the main cause of tissue-specific cancer development. MLL3/KMT2C and MLL4/KMT2D are two paralogous histone modifiers that belong to the SET1/MLL (also named COMPASS) family of lysine methyltransferases and play critical roles in enhancer-regulated gene activation. Importantly...
Biochem Soc Trans (2021) 49 (2): 675–683.
Published: 16 April 2021
...). Published by Portland Press Limited on behalf of the Biochemical Society 2021 cancer dimerization hippo pathway protein kinases SARAH domain signal transduction The Hippo pathway was originally discovered in Drosophila from genetic screens designed to identify pathways the regulate...
Biochem Soc Trans (2021) 49 (2): 843–854.
Published: 11 March 2021
...Joana G. Rodrigues; Henrique O. Duarte; Celso A. Reis; Joana Gomes Aberrant cell surface glycosylation signatures are currently known to actively drive the neoplastic transformation of healthy cells. By disrupting the homeostatic functions of their protein carriers, cancer-associated glycans...
Biochem Soc Trans (2021) 49 (1): 17–27.
Published: 18 February 2021
... and transcriptional networks. In this way, mitochondria are central to the cell's homeostatic machinery, and as such mitochondrial dysfunction underlies the pathology of a diverse range of diseases including mitochondrial disease and cancer. Mitochondrial import pathways and targeting mechanisms provide the means...
Biochem Soc Trans (2021) 49 (1): 93–105.
Published: 25 January 2021
... that belongs to the Fe-II dependent dioxygenase family that uses α-ketoglutarate and molecular oxygen as cofactors, is overexpressed in several cancers and is associated with an overall poor prognosis. KDM4A demethylates lysine 9 (H3K9me2/3) and lysine 36 (H3K36me3) methyl marks on histone H3. Given...
Biochem Soc Trans (2021) 49 (1): 269–280.
Published: 15 January 2021
... response. Given many cancers originate from point mutations in cancer-driving genes, the application of base editing for either modelling tumour development, therapeutic editing, or functional screening is of great promise. In this review, we summarise current DNA base editing technologies and will discuss...
Biochem Soc Trans (2020) 48 (6): 2691–2701.
Published: 26 November 2020
...Atanu Chakraborty Oncogenic mutation in KRAS is one of the most common alterations in human cancer. After decades of extensive research and unsuccessful drug discovery programs, therapeutic targeting of KRAS mutant tumour is at an exciting juncture. The discovery of mutation-specific inhibitors...
Biochem Soc Trans (2020) 48 (6): 2703–2719.
Published: 16 November 2020
... and survival, mainly through activating and directing Rac1 signalling. Dysregulation of the Tiam GEFs is significantly associated with human diseases including cancer, immunological and neurological disorders. Uncovering the mechanisms and consequences of dysregulation is therefore imperative to improving...
Biochem Soc Trans (2020) 48 (5): 1831–1841.
Published: 01 September 2020
...Mariyam Zuberi; Imran Khan; John P. O'Bryan RAS is a membrane localized small GTPase frequently mutated in human cancer. As such, RAS has been a focal target for developing cancer therapeutics since its discovery nearly four decades ago. However, efforts to directly target RAS have been challenging...
Biochem Soc Trans (2020) 48 (4): 1609–1621.
Published: 14 August 2020
...William A. Flavahan Epigenetic processes converge on chromatin in order to direct a cell's gene expression profile. This includes both maintaining a stable cell identity, but also priming the cell for specific controlled transitions, such as differentiation or response to stimuli. In cancer...
Biochem Soc Trans (2020) 48 (4): 1765–1780.
Published: 29 July 2020
... for structure-based drug design efforts targeting canonical Wnt signalling. beta-catenin cancer crystallography frizzled glycogen synthase kinase Wnt proteins Correspondence: Mark Agostino ( Mark.Agostino@curtin.edu.au ) or Sebastian Öther-Gee Pohl ( Sebastian.pohl@igmm.ed.ac.uk ) 26 5...
Biochem Soc Trans (2020) 48 (4): 1505–1518.
Published: 17 July 2020
... that, in a particular microenvironment, confer mutant lineages a fitness advantage relative to normal somatic cells do occur, and can result in cancer. This minireview highlights several views and paradigms that relate the evolution of multicellularity to cancer. As a phenomenon, cancer is generally understood...
Biochem Soc Trans (2020) 48 (3): 933–943.
Published: 26 May 2020
...Glorianne Lazaro; Eleftherios Kostaras; Igor Vivanco Aberrant activation of the PI3K pathway is one of the commonest oncogenic events in human cancer. AKT is a key mediator of PI3K oncogenic function, and thus has been intensely pursued as a therapeutic target. Multiple AKT inhibitors, broadly...
Biochem Soc Trans (2020) 48 (3): 955–969.
Published: 05 May 2020
...Tamara Bintener; Maria Pires Pacheco; Thomas Sauter Currently, the development of new effective drugs for cancer therapy is not only hindered by development costs, drug efficacy, and drug safety but also by the rapid occurrence of drug resistance in cancer. Hence, new tools are needed to study...
Includes: Supplementary data
Biochem Soc Trans (2020) 48 (2): 693–707.
Published: 20 April 2020
...Davide M. Ferraris; Edoardo L. M. Gelardi; Silvia Garavaglia; Riccardo Miggiano; Menico Rizzi Dehydrogenases are oxidoreductase enzymes that play a variety of fundamental functions in the living organisms and have primary roles in pathogen survival and infection processes as well as in cancer...
Biochem Soc Trans (2020) 48 (2): 595–612.
Published: 08 April 2020
..., as in cancer. In time, we hypothesize that many more ncRNA regulators of ribosome biogenesis will be discovered, which will be followed by an effort to establish connections between disease pathologies and the molecular mechanisms of this additional layer of ribosome biogenesis control. Figure 1. Ribosome...
Biochem Soc Trans (2020) 48 (2): 719–731.
Published: 08 April 2020
... different venoms demonstrate considerable cytotoxic effects on cancer cells via induction of apoptosis, cell cycle arrest and suppression of proliferation. These enzymes produce more pronounced cytotoxic effects in cancer cells than normal cells, thus they can be potential sources as chemotherapeutic agents...
Biochem Soc Trans (2020) 48 (1): 291–300.
Published: 12 February 2020
... that are in dire need of new therapeutic targets. These include cancer, immunotherapy, diabetes, obesity, and Alzheimer's disease. In this mini-review, we will provide a brief overview of research in these areas that support targeting SHIP1, SHIP2 or both enzymes for therapeutic purposes. Correspondence...
Biochem Soc Trans (2020) 48 (1): 301–315.
Published: 03 February 2020
... features and therapeutic failure in cancer. The aim of this review is to summarise current known and unknowns of PI3K-dependent stemness regulation, by integrating knowledge from the fields of developmental, signalling and cancer biology. Particular attention is given to the role of the PI3K pathway...
Biochem Soc Trans (2019) 47 (6): 1661–1678.
Published: 22 November 2019
...Jessica L. Chitty; Yordanos F.I. Setargew; Thomas R. Cox The extracellular matrix (ECM) is a fundamental component of tissue microenvironments and its dysregulation has been implicated in a number of diseases, in particular cancer. Tumour desmoplasia (fibrosis) accompanies the progression of many...
Biochem Soc Trans (2019) 47 (5): 1471–1479.
Published: 24 September 2019
...Jong Fu Wong; Elizabeth J. Brown; Eleanor Williams; Alex N. Bullock Brain tumours have become the leading cause of child mortality from cancer. Indeed, aggressive brainstem tumours, such as diffuse intrinsic pontine glioma (DIPG), are nearly uniformly fatal. These tumours display a unique set...
Biochem Soc Trans (2019) 47 (5): 1209–1222.
Published: 10 September 2019
...Dorota Sabat-Pośpiech; Kim Fabian-Kolpanowicz; Ian A. Prior; Judy M. Coulson; Andrew B. Fielding Due to cell-cycle dysregulation, many cancer cells contain more than the normal compliment of centrosomes, a state referred to as centrosome amplification (CA). CA can drive oncogenic phenotypes...
Biochem Soc Trans (2019) 47 (4): 997–1003.
Published: 18 July 2019
... and mammals, a pattern of global DNA hypomethylation coupled with increased methylation levels at some specific genomic regions arises at specific developmental stages and in certain abnormal cells, such as mammalian aging cells and cancer cells as well as some plant epigenetic mutants. Here we provide...
Biochem Soc Trans (2019) 47 (2): 743–754.
Published: 22 March 2019
... )-hydroxyeicosatetraenoic acid (HETE), an arachidonic acid metabolite, and the role that GPR31/12-HETER-mediated signals play in cancer cell growth, invasion and metastasis, and in liver ischemia–reperfusion (IR) injury. Recent studies shed light and interest on the 12( S )-HETE/GPR31/12-HETER-activated signaling pathways...
Biochem Soc Trans (2019) 47 (2): 725–732.
Published: 08 March 2019
... cells (heterotypic) or immune cells inside tumour cells (heterotypic). CIC formation can occur in cell lines and in tissues and it has been most frequently observed during inflammation and in cancers. Over the past 10 years, many researchers have studied CIC structures and a few different models have...
Biochem Soc Trans (2019) 47 (2): 559–569.
Published: 08 March 2019
...Ian J. Majewski The theory of evolution by natural selection shapes our understanding of the living world. While natural selection has given rise to all the intricacies of life on the planet, those responsible for treating cancer have a darker view of adaptation and selection. Revolutionary changes...
Biochem Soc Trans (2018) 46 (6): 1449–1462.
Published: 22 November 2018
... of transcription) and other signalling pathways are activated as a consequence. Of translational relevance, overexpression of IL-6 has been documented in several neoplastic disorders, including but not limited to colorectal, ovarian and breast cancer and several haematological malignancies. This review attempts...
Biochem Soc Trans (2018) 46 (6): 1517–1527.
Published: 12 November 2018
...Annalisa Contursi; Rosalia Grande; Melania Dovizio; Annalisa Bruno; Rosa Fullone; Paola Patrignani Platelets are involved in the development and progression of cancer through several mechanisms. Platelet activation at the site of tissue damage contributes to the initiation of a cascade of events...
Biochem Soc Trans (2018) 46 (6): 1681–1695.
Published: 12 November 2018
... the understanding of these pathways has provided some major breakthroughs in the treatment of human cancer. Correspondence: Luca Palazzo ( l.palazzo@ibp.cnr.it ) or Ivan Ahel ( ivan.ahel@path.ox.ac.uk ) 26 7 2018 15 9 2018 21 9 2018 © 2018 The Author(s) 2018 This is an open access...